Novartis stock

NOVN · SIX · CHF

CHF 135.64Change from previous close: +1.18%Absolute change: +CHF 1.58

Close · November 16, 2026

Price history

+28.23% over the period

1 year: from CHF 105.78 (November 17, 2025) to CHF 135.64 (November 16, 2026), +28.23%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026CHF 135.64
October 30, 2026CHF 133.78
September 30, 2026CHF 119.96
August 31, 2026CHF 123.26
July 31, 2026CHF 126.60
June 30, 2026CHF 126.58
May 29, 2026CHF 117.82
April 30, 2026CHF 115.90
March 31, 2026CHF 120.86
February 27, 2026CHF 130.50
January 30, 2026CHF 114.62
December 30, 2025CHF 109.60
November 28, 2025CHF 104.48
November 17, 2025CHF 105.78

At a glance

  • The company

    Researches, develops, manufactures and sells pharmaceutical medicines in Switzerland and internationally

  • Latest results

    Quarter to September 30, 2026 · EPS $2.46 (estimate $2.28)

TickerLandia's take on Novartis

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowCHF 99.45
52-wk highCHF 135.22

+0.31% from the 52-week high

Analysts · 23 analysts

Average targetCHF 129.21−4.74% vs. price

Buy 8 · Hold 11 · Sell 4 · Hold

TickerLandia Fingerprint: Novartis

Compared with similar companies: high dividend, low growth, and high profitability.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Novartis is pricier than similar companies

Novartis's P/E (trailing 12 months): 32.1, +50% against the median of a group of 10 similar companies (21.5).

Compared with 10 similar companies

Novartis's metrics compared with similar companies
MetricNovartisPosition in the groupBand
P/E (trailing 12 months)32.1High
Forward P/E16.2High
Operating margin34.0%High
ROE24.3%Middle
Debt/equity1.29High

Grey band: the middle half of the group; tick: the median; dot: Novartis. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$15.03B

Latest quarter · Q3 2026

Net income

$1.2B

Latest quarter · Q3 2026

Quarterly net margin

8.0%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
CHF 253.19B
P/E
32.1
EPS
CHF 4.17
Volume
3.38M
Daily trading
€500.59M
Dividend yield
2.73%
Last ex-dividend on March 10, 2026

How Novartis is changing

All results
  • Revenue grew 2.6% a year on average over the last 5 years

  • Operating margin rose from 21.2% to 33.5%

  • Profits turn into cash: free cash flow equal to 116% of net income

Returns

Novartis returns with dividends

CHF 1,000 invested in Novartis 5 years ago, on November 16, 2021, would be worth CHF 2,385 today with dividends reinvested: +138.49% in total, +18.99% per year. On price alone it would be CHF 1,871 (+87.07%).

PeriodNovartisSMICHF 1,000 becomes
1 month+8.77%+8.46%CHF 1,088
6 months+16.25%+14.27%CHF 1,162
Year to date+23.76%+13.86%CHF 1,238
1 year+32.12%+19.91%CHF 1,321
3 years+80.60%+41.93%CHF 1,806
5 years+138.49%+20.30%CHF 2,385
10 years+249.14%+90.88%CHF 3,491

Over the last 6 months it has done better than 28% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment

The chart in detail

Novartis: technical analysis

Novartis is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is at its all-time closing high.

Trend
Upward
RSI (14 sessions)
68
Between 30 and 70
vs 200-session average
+10.78%

Active signals

  • New 52-week high.

  • Close above the high of the previous 55 sessions.

Support and resistance

Price areas where Novartis has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last priceCHF 135.64
  3. SupportCHF 130.87−3.52%3 touches, last on November 6, 2026
  4. SupportCHF 128.29−5.42%2 touches, last on August 11, 2026
  5. SupportCHF 123.06−9.27%5 touches, last on September 30, 2026

Volatility and risk

Over the last year it has moved roughly in line with the SMI.

Beta (1 year) vs SMI
1.19
Volatility (60 sessions, annualised)
33.3%
Largest fall in the last year
−14.97%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Novartis: seasonality

Average monthly price change over 32 years

−0.8%Jan+0.9%Feb+0.7%Mar+1.3%Apr+0.6%May+1.7%Jun+0.6%Jul−0.4%Aug+1.1%Sep+0.2%Oct+1.9%Nov+0.7%Dec

Over the last 32 years, the strongest month for Novartis has been November: +1.89% on average, positive in 19 years out of 31. The weakest has been January: −0.83% on average, positive in 12 years out of 31.

Show chart data
MonthAverageMedianPositive years
January−0.83%−0.52%12 of 31
February+0.86%+0.57%18 of 31
March+0.66%+0.50%17 of 31
April+1.27%+1.73%20 of 31
May+0.64%+0.87%19 of 32
June+1.70%+1.09%22 of 32
July+0.63%+0.10%17 of 32
August−0.38%−0.58%16 of 32
September+1.14%+1.69%19 of 32
October+0.20%−0.68%13 of 32
November+1.89%+2.43%19 of 31
December+0.67%+0.57%18 of 31

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Novartis and its competitors

With 75,267 employees, the Swiss pharmaceutical group researches, develops, manufactures and sells prescription medicines in Switzerland and across the world. Its portfolio includes Entresto for chronic heart failure, Cosentyx for psoriasis and spondylitis, Kisqali, an oral kinase inhibitor, Pluvicto for advanced prostate cancer and Zolgensma for spinal muscular atrophy. Leqvio, which lowers LDL cholesterol, is developed under a license and collaboration agreement with Alnylam Pharmaceuticals. Its research and sales focus on heart and kidney disease, metabolic conditions, immunology, neuroscience, oncology and hematology.

Headquarters
Basel, Switzerland
Employees
75,267
Founded
1996
Chief executive
Vasant Narasimhan
Novartis and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
NovartisNOVN$301.99B34.0%32.1+16.25%
AstraZenecaAZN$286.82B25.8%26.5+2.92%
Roche HoldingROP$384.6B33.1%26.4+26.27%
Novo NordiskNOVO.B$181.48B50.8%10.9−3.84%
SanofiSAN$116.24B22.3%25.3+18.71%
GSKGSK$101.36B30.5%17.9+3.57%

Same industry or related industries, similar size. Compare Novartis with its competitors · Full profile